Immunomodulation_of_the_induction_phase_of_lymphokine-activated_killer_activity_by_acute_phase_proteins._Effective_treatment_of_head_and_neck_cancer_with_biologic_response_modifiers_may_be_benefitted_by_an_understanding_of_in_vivo_factors_capable_of_modulating_the_lymphokine-activated_killer_(LAK)_cell_phenomenon._Eighteen_patients_with_squamous_cell_carcinoma_of_the_head_and_neck_were_studied._Killer_cells_from_each_patient,_activated_by_recombinant_interleukin-2_(10_U/ml),_were_induced_in_either_complete_medium_alone_or_complete_medium_plus_10%_autologous_serum_solution_and_analyzed._Cytotoxicity_against_both_K562_and_squamous_cell_carcinoma_(MDA686-Ln)_cell_lines_was_determined_by_use_of_standard_chromium-release_assays._The_immunomodulatory_capacity_of_serum_was_correlated_with_levels_of_various_acute_phase_proteins._Autologous_serum_significantly_inhibited_the_induction_phase_of_the_LAK_phenomenon_in_61%_of_patients_and_stimulated_it_in_22%._No_patients_with_early_stage_I_or_II_disease_had_significant_inhibition_of_induction._No_direct_correlation_between_inhibition_and_serum_acute_phase_protein_levels_were_seen._An_inverse_relationship_was_seen_between_the_C3_component_of_complement_and_induction_inhibition_(r_=_-0.6)._These_findings_suggest_that_advances_of_in_vivo_immunomodulatory_therapy_will_require_elucidation_of_mechanisms_of_serologic_inhibition_of_the_induction_phase_of_the_LAK_phenomenon._Such_studies_may_lead_to_serologic_modification_to_enhance_treatment_efficacy_of_biologic_response_modifiers.